{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.11","estimateComment":"Hazard ratio: Arm B/Arm A","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.83"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.766","upperLimit":"0.846","value":"0.805"},{"groupId":"OG001","lowerLimit":"0.796","upperLimit":"0.871","value":"0.833"},{"groupId":"OG002","lowerLimit":"0.791","upperLimit":"0.842","value":"0.816"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"424"},{"groupId":"OG001","value":"435"},{"groupId":"OG002","value":"998"}],"units":"Participants"}],"description":"Disease-free survival (DFS) is defined as the time from randomization to the earlier of disease recurrence, new invasive primary cancer, or death from any cause. The Kaplan-Meier estimates were used to characterize the 5-year DFS rates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (5-FU, Leucovorin, Oxaliplatin)"},{"description":"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (5-FU, Leucovorin, Oxaliplatin, Bevacizumab)"},{"description":"Patients undergo observation.","id":"OG002","title":"Arm C (Observation)"}],"paramType":"NUMBER","populationDescription":"Eligible patients who were registered or randomized at Step 2 were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization","title":"Disease-free Survival Rate at 5 Years","type":"PRIMARY","unitOfMeasure":"Proportion of participants"}